Germline-targeting immunogens guide bnAb development

Developing a vaccine against HIV is notoriously difficult due to the virus's high mutation rate and the extensive glycosylation of its envelope (Env) glycoprotein. Broadly neutralizing antibodies (bnAbs) are capable of blocking most HIV strains, but they are rarely produced by the human immune system because the conserved sites they target—such as the membrane-proximal external region (MPER)—are poorly accessible and often hidden by the viral membrane. Furthermore, the unmutated common ancestors (UCAs) of these bnAbs typically lack the affinity required to be activated by standard vaccines.

To overcome these barriers, researchers are employing a germline-targeting strategy. This approach uses engineered scaffold proteins designed to bind the UCAs of specific bnAb lineages with high affinity, thereby recruiting them into germinal centers (GCs) where they can undergo affinity maturation. By creating an 'affinity gradient'—where subsequent immunogens more closely resemble the native viral epitope—scientists hope to guide these B cells through the complex evolutionary steps necessary to produce mature bnAbs.

Two recent studies demonstrate the feasibility of this approach for the 10E8 bnAb lineage, which targets the MPER. Using structure-based design and directed evolution, the researchers created stable scaffold proteins (10E8-GT) that successfully recruited 10E8-lineage B cells in transgenic mouse models and non-human primates. These studies highlight the importance of immunogen formulation, such as multimerization and the use of specific adjuvants, to ensure that the targeted B cells are not outcompeted by other, faster-mutating B cell populations in the germinal center.

This work represents a significant step toward 'precision vaccines' for HIV. By proving that we can selectively activate and steer specific, rare B cell lineages toward a desired bnAb phenotype, these findings provide a blueprint for designing sequential immunization regimens. While a single immunogen is insufficient to generate a fully functional bnAb, the ability to reliably initiate the correct B cell response is a critical prerequisite for any effective HIV vaccine.